Connect your agent to akta.pro and build company lists like this across sectors and geos.
Private US biotech startups companies, Series A or later, ranked by Q3 2026 primary-subject news volume: funding, products and services, revenue model, news signals and headcount growth for each.
| Company | Funding | Products & Services | Revenue Model | Signals (Q3 2026) | Headcount growth (Q3) |
|---|---|---|---|---|---|
| Chai Discovery ↗ AI Drug Discovery 🇺🇸 San Francisco, USA | Funding $631.0M Last raised $400.0M Jul 2026 · Series C | Generative foundation models (Chai-1, Chai-2, Chai-3) predicting biomolecular structure and designing de novo antibodies and miniproteins, licensed to Eli Lilly and Pfizer. | Licensing Royalties Subscription Recurring Professional Services | 55 in Q3 View signals (29) → | +15% in Q3 39 → 45 employees |
| Colossal Biosciences ↗ Biotechnology 🇺🇸 Austin, USA | Funding $628.1M Last raised $60.0M Feb 2026 · Series C | CRISPR, ancient DNA and reproductive biology applied to de-extinction of six species, plus genetic-rescue, BioVault preservation and pet-cloning services via its Viagen subsidiary. | Transaction Fee Subscription Recurring Managed Services Licensing Royalties | 42 in Q3 View signals (34) → | -1% in Q3 269 → 266 employees |
| Enveda Biosciences ↗ Natural Product Drug Discovery 🇺🇸 Boulder, USA | Funding $840.9M Last raised $311.0M Sep 2026 · Series E | AI platform (PRISM) combining mass spectrometry with the world's largest plant-derived molecule library, advancing three clinical-stage small-molecule candidates for inflammation and metabolic disease. | Licensing Royalties Subscription Recurring Transaction Fee | 39 in Q3 View signals (11) → | -3% in Q3 400 → 387 employees |
| Treeline Biosciences ↗ Precision Oncology Drug Discovery 🇺🇸 Watertown, USA | Funding $1.09B Last raised $200.0M Sep 2025 · Series A | Clinical-stage biopharma using a cloud-first computational and machine-learning discovery platform, advancing three Phase 1 precision oncology candidates targeting BCL6, EZH2 and KRAS. | Subscription Recurring Licensing Royalties | 28 in Q3 View signals (14) → | +4% in Q3 167 → 174 employees |
| Orca Bio ↗ Cell Therapy / Biologics 🇺🇸 Menlo Park, USA | Funding $542.0M Last raised $250.0M Jan 2026 · Series F | High-precision allogeneic T-cell immunotherapy using single-cell precision for hematologic malignancies; lead asset Orca-T is under FDA Priority Review with a July 2026 PDUFA date. | One Time License | 25 in Q3 View signals (16) → | +6% in Q3 366 → 389 employees |
| LifeMine Therapeutics ↗ Drug Discovery & Development 🇺🇸 Cambridge, USA | Funding $563.0M Last raised $188.0M Aug 2026 · Series E | Avatar-Rx platform mines fungal genomes via AI and synthetic biology for genetically encoded small molecules; lead asset LIFE-001 is in Phase 1 for immune disorders and transplant rejection. | One Time License Licensing Royalties | 24 in Q3 View signals (15) → | +23% in Q3 30 → 37 employees |
| Aureka Biotechnologies ↗ AI-driven antibody therapeutics discovery 🇺🇸 Laguna Hills, USA | Funding $168.4M Last raised $100.0M Aug 2026 · Series B | AuraIDE platform combining high-throughput synthetic biology, microfluidic screening and a protein language model to design antibodies for pharma partners and an internal pipeline. | Professional Services Licensing Royalties | 23 in Q3 View signals (9) → | +8% in Q3 39 → 42 employees |
| EGenesis ↗ Xenotransplantation Therapeutics 🇺🇸 Cambridge, USA | Funding $470.0M Last raised $14.0M Aug 2026 · Convertible note | EGEN multiplex CRISPR platform producing human-compatible porcine kidneys and livers, with lead kidney and liver candidates in FDA-cleared clinical trials. | Licensing Royalties | 21 in Q3 View signals (7) → | -1% in Q3 157 → 156 employees |
| Moonwalk Biosciences ↗ Epigenetic Therapeutics 🇺🇸 South San Francisco, USA | Funding $127.0M Last raised $70.0M Sep 2026 · Series B | EpiRead and EpiWrite epigenetic profiling and engineering platforms, with AI-guided target discovery driving a preclinical obesity and cardiometabolic pipeline. | Licensing Royalties | 21 in Q3 View signals (3) → | +5% in Q3 20 → 21 employees |
| Encoded Therapeutics ↗ Neurological Gene Therapy 🇺🇸 South San Francisco, USA | Funding $514.1M Last raised $275.0M Sep 2026 · Series F | One-time AAV-based gene regulation therapies using a Genetic Medicines Product Engine; lead program ETX101 is in pivotal trials for SCN1A+ Dravet syndrome. | One Time License | 18 in Q3 View signals (6) → | +6% in Q3 186 → 198 employees |
| InduPro ↗ Biotechnology Therapeutics 🇺🇸 Seattle, USA | Funding $162.0M Last raised $77.0M Aug 2026 · Series B | Proximity-based protein therapeutics using an AI-enabled membrane interactomics platform to design bispecific antibodies, ADCs and T-cell engagers licensed to major pharma. | Licensing Royalties Professional Services Subscription Recurring | 16 in Q3 View signals (11) → | +2% in Q3 61 → 62 employees |
| Abcuro ↗ Biopharmaceuticals 🇺🇸 Newton, USA | Funding $520.2M Last raised $66.0M Aug 2026 · Series D | First-in-class anti-KLRG1 monoclonal antibody depleting cytotoxic T cells; lead asset ulviprubart is in late-stage trials for inclusion body myositis and T-cell leukemia. | One Time License | 14 in Q3 View signals (8) → | -3% in Q3 35 → 34 employees |
| BigHat Biosciences ↗ Antibody Discovery Platform 🇺🇸 San Mateo, USA | Funding $174.3M Last raised $75.0M Sep 2026 · Series C | Milliner platform pairing cell-free synthetic biology with machine learning in a weekly design-build-test-learn loop, partnered with Lilly, J&J, AbbVie, Amgen and Merck. | Professional Services Licensing Royalties | 14 in Q3 View signals (4) → | +1% in Q3 97 → 98 employees |
| BrainChild Bio ↗ CAR-T Immunotherapy 🇺🇸 Seattle, USA | Funding $116.3M Last raised $116.0M Sep 2026 · Series A | Autologous CAR T-cell therapies for brain tumors using intracerebroventricular dosing to bypass the blood-brain barrier; lead candidate BCB-276 targets DIPG. | One Time License | 14 in Q3 View signals (1) → | +9% in Q3 54 → 59 employees |
| Vedanta Biosciences ↗ Microbiome Therapeutics 🇺🇸 Cambridge, USA | Funding $477.0M Last raised $40.0M Aug 2026 · Series Unknown | Oral Live Biotherapeutic Products made of defined bacterial consortia; lead asset VE303 is in pivotal Phase 3 for recurrent C. difficile infection. | One Time License | 13 in Q3 View signals (6) → | -1% in Q3 86 → 85 employees |
| Wugen ↗ Oncology Cell Therapy 🇺🇸 St Louis, USA | Funding $322.0M Last raised $35.0M Jul 2026 · Series C | Allogeneic, off-the-shelf CAR-T and memory NK cell therapies using CRISPR gene editing; lead candidate Sofi-cel is in pivotal Phase 2 for T-cell leukemia/lymphoma. | One Time License | 13 in Q3 View signals (7) → | +6% in Q3 47 → 50 employees |
| City Therapeutics ↗ RNAi Therapeutics 🇺🇸 Cambridge, USA | Funding $234.5M Last raised $99.5M Jun 2026 · Series B | Next-generation RNAi medicines using proprietary cityRNA trigger molecules and extra-hepatic delivery, targeting Factor XI and RBP4 for clotting and retinal diseases. | One Time License Licensing Royalties | 13 in Q3 View signals (3) → | +4% in Q3 89 → 93 employees |
| Superluminal Medicines ↗ AI-powered drug discovery services 🇺🇸 Boston, USA | Funding $223.5M Last raised $65.5M Sep 2026 · Series B | Hyperloop AI platform combining protein dynamics, generative chemistry and cryoEM structural biology to discover small-molecule GPCR therapeutics for pharma partners. | Licensing Royalties Professional Services | 13 in Q3 View signals (6) → | +7% in Q3 61 → 65 employees |
| Beeline Medicines ↗ Autoimmune Therapeutics 🇺🇸 Boston, USA | Funding $426.3M Last raised $126.3M Jun 2026 · Series A | Five-program precision immunology pipeline licensed from Bristol Myers Squibb; lead asset afimetoran is in Phase 2 for systemic lupus erythematosus. | One Time License | 12 in Q3 View signals (8) → | +21% in Q3 57 → 69 employees |
| Caldera Therapeutics ↗ Bispecific Antibody Therapeutics 🇺🇸 Cambridge, USA | Funding $112.5M Last raised $37.5M Jan 2026 · Series A | CLD-423, a first-in-class bispecific antibody targeting IL-23p19 and TL1A pathways for inflammatory bowel disease, now in a Phase 1 healthy volunteer trial. | One Time License | 11 in Q3 View signals (4) → | n/d |
A biotech startup is a venture-backed company developing medicines or biological technologies from living systems, such as antibodies, cell and gene therapies, RNA drugs and engineered proteins.
Cell and gene medicine is a large segment in the table: Orca Bio, Wugen and BrainChild Bio develop cell therapies, and Encoded Therapeutics and EGenesis work on gene therapy and engineered organs.
AI-enabled discovery companies such as Chai Discovery, Enveda Biosciences, Aureka Biotechnologies, BigHat Biosciences and Superluminal Medicines use computation to find drug candidates. Treeline Biosciences, Abcuro, Beeline Medicines and Caldera Therapeutics advance their own pipelines.
Platform outliers include Colossal Biosciences in genetic engineering and Vedanta Biosciences in microbiome therapies. The category is defined against large public pharma and biotech, which often partner with or acquire these startups.
Revenue in the table, where reported, comes from licensing and partnership deals, since most companies are pre-commercial. None of the 20 prices on usage.
Companies are tagged against standard industry codes and against akta.pro's internal taxonomy, so the same set can be rebuilt by code, by segment, or by a combination of both.
NAICSIndustry codes are provided for cross-referencing against public filings and procurement records. akta.pro classification is independent of them, so a company may carry an internal segment without a matching NAICS or SIC registration.